ISRCTN13623634已完成3 期
A multicentre Phase III double-masked randomised controlled non-inferiority trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for macular oedema due to central retinal vein occlusion
Moorfields Eye Hospital (UK)0 个研究点目标入组 463 人开始时间: 2014年11月26日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 463
研究概览
简要总结
2016 protocol in: https://www.thelancet.com/protocol-reviews/14PRT-06545 2019 results in https://www.ncbi.nlm.nih.gov/pubmed/31465100 (added 01/11/2019) 2021 results in https://pubmed.ncbi.nlm.nih.gov/34132192/ (added 17/06/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Subjects of either sex aged = 18 years
- •2. Clinical diagnosis of centre-involving macular oedema (MO) due to CRVO
- •3. CRVO of = 12 months duration
- •4. Best corrected visual acuity in the study eye = 19 and = 73 ETDRS letters (approximate Snellen VA 3/60 to VA 6/12)
- •5. Best corrected visual acuity in the non-study eye = 14 ETDRS letters (approximate Snellen VA = 2/60).
- •6. SD-OCT central subfield thickness (CST) > 320µm (Spectralis) predominantly due to MO secondary to CRVO in the study eye. See appendix 1 for equivalent CST value for alternative SD-OCT machines.
- •7. Media clarity, pupillary dilatation and subject cooperation sufficient for adequate fundus imaging of the study eye
- •8. In cases of bilateral CRVO, if both eyes are potentially eligible, unless the patient prefers otherwise the worst seeing eye will be recruited
排除标准
- •Current exclusion criteria as of 13/08/2018:
- •The following apply to the study eye only and to the non-study eye only where specifically stated:
- •1. Macular oedema considered to be due to a cause other than CRVO (e.g. diabetic macular oedema, Irvine-Gass syndrome).
- •2. An ocular condition is present that, in the opinion of the investigator, might affect macular oedema or alter visual acuity during the course of the study (e.g. vitreomacular traction)
- •3. Any previously documented diabetic retinopathy or diabetic macular oedema in the study eye at baseline clinical examination of the study eye.
- •4. Moderate or severe non proliferative diabetic retinopathy (NPDR) or quiescent, treated or active proliferative diabetic retinopathy (PDR) or macular oedema in the non-study eye. Note: Mild NPDR only is permissible in the non-study eye.
- •5. History of treatment for MO due to CRVO in the past 90 days with intravitreal or peribulbar corticosteroids or in the last 60 days with anti-VEGF drugs or >6 prior anti-VEGF treatments in the previous 12 months.
- •6. Active iris or angle neovascularisation, neovascular glaucoma, untreated NVD, NVE and vitreous haemorrhage or treatment for these conditions in the last 1 month.
- •7. Uncontrolled glaucoma [>30mmHg], either untreated or on anti-glaucoma medication at screening.
- •8. Any active periocular or intraocular infection or inflammation (e.g. conjunctivitis, keratitis, scleritis, uveitis, endophthalmitis).
- •Systemic exclusion criteria:
- •9. Uncontrolled blood pressure defined as a systolic value > 170mmHg and diastolic value > 110mmHg.
- •10. Myocardial infarction, stroke, transient ischaemic attack, acute congestive cardiac failure or any acute coronary
- •event < 3 months before randomisation
- •11. Women of child bearing potential unless using effective methods of contraception throughout the study and for 6 months after their last injection for the trial. Effective contraception is defined as one of the following:
- •11.1. Barrier method: condoms or occlusive cap with spermicides
- •11.2. True abstinence: When it is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
- •11.3. Have had tubal ligation or bilateral oophorectomy (with or without hysterectomy)
- •11.4. Male partner sterilisation. The vasectomised male partner should be the only partner for the female participant
- •11.5. Use of established oral, injected or implanted hormonal methods of contraception and intrauterine device
- •12. Pregnant or lactating women.
- •13. Males who do not agree to an effective form of contraception for the duration of the study and for 6 months after their last injection for the trial
- •14. Hypersensitivity to the active ingredients aflibercept, bevacizumab or ranibizumab or any of the excipients of these drugs
- •15. Hypersensitivity to Chinese Hamster Ovary (CHO) cell products or other recombinant human or humanised antibodies
- •16. A condition that, in the opinion of the investigator, would preclude participati
研究者
相似试验
已完成
不适用
Adjunctive steroid combination in ocular trauma studyTopic: OphthalmologySubtopic: Eye (all Subtopics)Disease: OphthalmologyEye DiseasesOpen-globe ocular traumaISRCTN30012492Moorfields Eye Hospital NHS Foundation Trust (UK)300
已完成
3 期
IgNiTE: Immunoglobulin in the treatment of encephalitisEncephalitisNervous System DiseasesEncephalitis, myelitis and encephalomyelitis, unspecifiedISRCTN15791925niversity of Oxford18
终止
3 期
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)Neovascular Age-related Macular DegenerationNCT04757610Opthea Limited986
终止
3 期
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)Neovascular Age-related Macular DegenerationNCT04757636Opthea Limited998
已完成
3 期
A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)Age-Related Macular DegenerationNCT03150589Samsung Bioepis Co., Ltd.705